To our knowledge, this is the first systematic review of real-world evidence to describe residual disease burden among patients with psoriatic arthritis who have received treatment and been assessed against treatment targets.

This study demonstrates the breadth of different symptoms that can persist despite treatment, even among those patients who have achieved stringent treatment targets.

Residual musculoskeletal and skin disease were frequently observed, as well as residual patient-reported pain, fatigue, disability and disease impact on patients’ lives.

Our findings demonstrate the variability of residual disease seen with different targets; they also indicate a possible discordance between patients’ and physicians’ perspectives of disease control and treatment success.

This review highlights the need for further optimisation of care for patients with psoriatic arthritis.